OSE Immunotherapeutics to Present New Preclinical Data at Upcoming Bispecific Antibody and Immunology Conferences
New Data Supporting Bispecific Antibody Checkpoint Inhibitor Platform (BiCKI) and Bifunctional Therapy Targeting PD1 and IL-7 (BiCKI-IL-7) For Cancer Immunotherapy Regulatory News: OSE Immunotherapeutics
Source: finanznachrichten.de